Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is... see more

Recent & Breaking News (GREY:ATNXQ)

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

GlobeNewswire May 14, 2023

Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO

PR Newswire May 1, 2023

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

GlobeNewswire March 20, 2023

Athenex Announces a Reverse Stock Split

GlobeNewswire February 14, 2023

Athenex Announces MHRA Decision on Oral Paclitaxel

GlobeNewswire January 3, 2023

Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

GlobeNewswire December 20, 2022

Athenex Exits 503B Sterile Compounding Business

GlobeNewswire December 16, 2022

Athenex Announces Positive Results of Special Stockholder Meeting

GlobeNewswire November 22, 2022

Athenex Announces Closing of the Sale of its China API Business

GlobeNewswire November 21, 2022

Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 8, 2022

Athenex Announces Receipt of Positive Nasdaq Listing Determination

GlobeNewswire November 3, 2022

Athenex Provides Third Quarter 2022 Financial Results and Business Update

GlobeNewswire November 3, 2022

Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

GlobeNewswire October 24, 2022

Athenex Files Definitive Proxy Statement for Special Stockholder Meeting

GlobeNewswire October 11, 2022

Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

GlobeNewswire August 11, 2022

Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

GlobeNewswire August 10, 2022

Athenex Provides Second Quarter 2022 Financial Results and Business Update

GlobeNewswire July 28, 2022

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology

GlobeNewswire July 25, 2022

Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

GlobeNewswire July 21, 2022